Eprontia is owned by Azurity.
Eprontia contains Topiramate.
Eprontia has a total of 2 drug patents out of which 0 drug patents have expired.
Eprontia was authorised for market use on 05 November, 2021.
Eprontia is available in solution;oral dosage forms.
Eprontia can be used as indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age and older; indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; indicated for the preventive treatment of migraine in patients 12 years and older.
The generics of Eprontia are possible to be released after 21 August, 2040.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11633374 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(17 years from now) | |
US11433046 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(17 years from now) |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 05 November, 2021
Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age ...
Dosage: SOLUTION;ORAL
5
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic